Perspectives of gammadelta T cells in tumor immunology.

Abstract

Subsets of human gammadelta T cells recognize tumor cell-expressed ligands that are not seen by the T-cell receptor of conventional alphabeta T cells. Vdelta1 T cells recognize MHC class I chain-related molecules A and B and UL-16-binding proteins expressed at variable levels on epithelial tumor cells and some leukemias and lymphomas. In addition, therapeutically used aminobisphosphonates and synthetic phosphoantigens activate Vdelta2 T cells, the dominant subset of gammadelta T cells in human peripheral blood that display strong cytotoxicity towards various epithelial tumors. Intentional activation of gammadelta T cells in vivo and/or adoptive cell therapy with in vitro expanded gammadelta T cells holds considerable promise as a novel immunotherapy in certain types of cancer.

• Authors: Dieter Kabelitz, Daniela Wesch, Wei He
• Journal: Cancer research (Cancer Res) Vol. 67 Issue 1 Pg. 5-8 (Jan 01 2007) ISSN: 0008-5472 [Print] United States
• PMID: 17210676 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antigens, Neoplasm
• Receptors, Antigen, T-Cell, gamma-delta

Topics

• Antigens, Neoplasm (immunology)
• Humans
• Neoplasms (immunology)
• Receptors, Antigen, T-Cell, gamma-delta (immunology)